INNOVATE Corp.

INNOVATE Corp. is a diversified holding company headquartered in New York, New York, with a strategic focus on acquiring and managing businesses across infrastructure, life sciences, and spectrum sectors. The company's mission centers on long-term value creation through enhancing the performance of its portfolio companies and is dedicated to stakeholder capitalism.

The company operates through three primary segments. Its Infrastructure segment, primarily DBM Global, provides industrial construction, structural steel fabrication and erection, and facility maintenance services for large-scale commercial, industrial, and infrastructure projects. The Life Sciences segment, through Pansend Life Sciences, supports healthcare and biotechnology product development, including companies like MediBeacon, which focuses on kidney function assessment, and R2 Technologies, which develops aesthetic and medical skin technologies. The Spectrum segment, managed by HC2 Broadcasting, operates over-the-air broadcasting stations across the United States.

Recent developments include MediBeacon receiving FDA approval for its TGFR system in December 2025 and a CE Mark in March 2026, while its portfolio company DBM Global paid a cash dividend in April 2026. Paul K. Voigt serves as the Interim Chief Executive Officer, appointed in July 2023, with Avram Glazer as Chairman of the Board. INNOVATE Corp. is publicly traded on the NYSE under the ticker symbol VATE.